The company announces positive topline data from its pivotal phase III ADVOCATE trial for avacopan.
The test achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks.
Other notes: Significantly reduced glucocorticoid toxicity, significantly improved kidney function compared to glucocorticoid-containing SOC, improved health-related quality of life measures compared to SOC
A conference call is just underway.
CCXI +265.4%
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.